CAPS Rating: No stars


Player Avatar TMFCop (84.18) Submitted: 1/18/2008 6:58:25 AM : Outperform Start Price: $41.60 ESALY Score: -5.69

Although it faces patent expiration on a number of its top products within a short time frame and Teva recently got approval to market a generic version of Aricept, Eisai can still stop it from coming to market with the court case it has pending.

Moreover, Eisai has moved strongly into the oncology field and is spreading its reach beyond just Alzheimer's and heartburn.

As the fourth largest pharmaceutical in Japan with a good size portfolio underpinning it, it would not surprise me if Eisai is one day acquired by its U.S. brethren. Until that time, though, I see it beating the market handily in both the short term and long term.

Featured Broker Partners